Single-Use Vials and Drug Waste: When the Same Quantity Is Billed Twice

Single-use vial drug waste billing fraud occurs when a practice knowingly bills government health care programs for drug quantities that its purchases, treatment and discarded amounts do not support. A patient can receive real medication while the bill tells a false story about the vial it came from. If you prepare the doses, manage inventory or submit claims, you may see the same drug counted differently as it moves through the practice. That discrepancy is where this kind of physician billing fraud comes into view.

What Is the CMS Policy on Drug Waste?

Medicare Part B pays for eligible discarded drug from a single-dose container after a dose is administered, up to the amount on the vial or package label when the administered and discarded amounts are combined. The claim must connect the quantity administered, the quantity discarded and the drug’s HCPCS billing unit.

Under CMS’s discarded-drug policy, JW identifies eligible discarded drug on a separate claim line. CMS required it nationally for applicable claims beginning January 1, 2017. JZ identifies no discarded amount eligible for payment and became required for applicable claims no later than July 1, 2023. Both concern separately payable Part B drugs supplied in single-dose containers or single-use packages.

The payment setting matters. Drugs packaged into a hospital outpatient or ambulatory surgical center payment fall outside this modifier policy, as do drugs administered in rural health clinics and federally qualified health centers. We connect the service date, setting and drug to the payment rule before comparing the quantities.

When Rounding Has Already Paid for the Remainder

A billing unit can include both the administered dose and its discarded remainder. CMS’s Medicare Claims Processing Manual gives an example in which one billing unit represents 10 mg, the patient receives 7 mg and the remaining 3 mg is discarded. The administered-dose line bills one unit, which already pays for the whole amount. A second unit with JW would pay again for a remainder already covered.

The manual requires JZ in that circumstance under the later modifier policy. That is why a JZ line has to be read alongside the dose and billing unit: physical discard and an additional payable waste quantity are different things. Treating every remainder as another billable unit is how a small quantity can become a second charge.

Can JZ and JW Modifiers Be Billed Together?

They can appear on different lines of certain large claims under CMS’s instructions. In the ordinary waste claim, the administered line has no waste modifier and the discarded line carries JW. We connect those lines to the dose and discard records to see what quantity the practice asked Medicare to pay for.

Why Overfill Is Never Billable Waste

Overfill is drug beyond the quantity identified on the package or label, and CMS prohibits billing for it. It also prohibits using JW to report discarded overfill. An extra amount physically present in the container does not increase its labeled payable quantity.

The single-dose modifier policy also excludes drugs from multidose containers. For the office drug claim, the vial’s labeling, the prescribed dose and the actual discard belong together. CMS encourages efficient, clinically appropriate drug use, so the vial size selected is part of understanding how the remainder arose. We examine the container actually used and the quantities recorded against it.

When the Same Quantity Is Billed Twice

The duplication can happen across patients or within one patient’s claim. Across patients, a shared vial can generate bills representing a separate vial for each person. Within a claim, an administered billing unit can already contain the remainder that a second line attempts to charge again. Both problems become visible when the billed units are connected to the physical drug.

In buy-and-bill, the practice acquires the drug, holds inventory, administers treatment and bills for the covered drug and administration services. Medicare’s payment limits apply to the drug’s billing units. That makes the gap between incoming inventory and outgoing claim quantities worth following: extra units on a bill can mean extra government payment.

No-cost deliveries also belong in the inventory account, and their eligibility for reimbursement needs its own examination. We trace the drug from its source through the dose and discard to the transmitted claim. Otherwise, a real treatment can conceal a false representation about what the practice paid for or how much drug it supplied.

CMS also uses discarded-drug reporting to calculate refunds owed by manufacturers for certain single-dose products. Incomplete JW reporting led it to introduce JZ, so the waste entry feeds both the practice’s payment request and the government’s accounting of discarded drug.

Progressive Oncology and the Vial Billed to Each Patient

Progressive Oncology & Hematology, a chemotherapy practice in Frederick, Maryland, and its owner and sole provider agreed to pay $1.45 million to resolve False Claims Act allegations. In its July 2026 settlement announcement, the Justice Department described different ways the drug bill allegedly departed from what the practice acquired or administered.

First, the government alleged that the practice and its owner billed Medicare, Medicaid and the Department of Veterans Affairs for chemotherapy obtained at no expense through charitable organizations or grants for specific patients. The drugs’ source mattered alongside their administration. A treatment record and the charity’s delivery record would answer different parts of the reimbursement question.

The government also alleged that they directed staff to split wastage from single-use vials across two or more patients, then billed as though each patient had received a separate vial. We see the absurdity in the alleged arrangement: the practice stretched the medication across patients while the bills multiplied the containers. An insider who saw how doses were prepared could connect that work to a billing representation invisible from a single patient’s claim.

Finally, the government alleged that the practice and its owner billed for chemotherapy prescribed but never administered there. Here the question reaches the treatment itself, with the order on one side and the administration record on the other. HHS’s Office of Inspector General and the Department of Veterans Affairs Office of Inspector General investigated the case.

Ophthalmic Consultants and the Drug Behind the Units

Ophthalmic Consultants in Sarasota, Florida, and its physician agreed to pay $4.8 million to resolve allegations involving single-use eye medications. The Justice Department’s June 2020 announcement alleged excessive reimbursement from Medicare, TRICARE and the Federal Employees Health Benefits Program for treatments using Lucentis and Eylea. The government alleged that the practice used individual vials to provide doses to multiple patients.

The announcement describes moderate overfill in those vials and identifies both products as single-use medications. To follow that allegation, we put purchased drug, administered drug and billed units beside one another. Overfill, labeled contents and a separately acquired vial are different quantities in that comparison.

The settlement also included an integrity agreement with the Office of Inspector General requiring routine inventory checks and attention to proper billing and reimbursement claims. Inventory belongs at the center of this story: the government paired the billing resolution with requirements concerning the stock behind the claims.

What Evidence Does a Whistleblower Need?

Useful evidence connects the drug that entered the practice to the treatment, discard and claim. The invoice, lot record, administration entry and bill describe different stages of the same transaction. We work with the insider who can explain where their quantities stopped agreeing.

The handoff between clinical and billing systems deserves particular attention. We compare the clinical quantity with the quantity the billing system received, including any automatic calculation between them. CMS requires an accurately documented discarded amount, however the software calculates it.

Who Chose the Quantity on the Claim?

The person who understands the mismatch can also explain how it reached the bill. A preparation instruction, a billing-system setting or a warning followed by continued claims can connect the numbers to decisions inside the business. We examine those decisions alongside the drug records when assessing a physician practice qui tam case.

When a management company controls billing, the work includes identifying who could set or change those instructions. In a healthcare business, clinical work, administrative functions and authority over claim preparation can sit in different hands. Your knowledge of who directed the work helps us follow the discrepancy to the people responsible for it.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We connect what you know about the drug handling and billing decisions to the government’s payment, building the case with you and physician practice fraud whistleblower lawyers who understand drug reimbursement.

You Saw What Happened to the Vial

If the drug you prepared, tracked or billed tells a different story from the claim, speak with our whistleblower experts about that difference. We bring the inventory, clinical records and billing decisions together with you, find whistleblower lawyers who know physician drug billing, and stay beside you as the case develops. Your view inside the practice is the starting point for making the government see what its claims data cannot show alone.